Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland Jr, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild and Alex A. Adjei A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer Cancer 116
Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25448
Sorafenib is not effective as front-line therapy in the general unselected nonsmall cell lung cancer population.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field